Profund Advisors LLC Sells 5,748 Shares of Eli Lilly And Co (NYSE:LLY)

Profund Advisors LLC lessened its stake in Eli Lilly And Co (NYSE:LLY) by 15.3% during the second quarter, Holdings Channel reports. The firm owned 31,879 shares of the company’s stock after selling 5,748 shares during the period. Profund Advisors LLC’s holdings in Eli Lilly And Co were worth $3,532,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Meridian Wealth Management LLC bought a new position in shares of Eli Lilly And Co in the first quarter valued at approximately $38,000. Manchester Financial Inc. bought a new stake in Eli Lilly And Co during the second quarter worth $40,000. Litman Gregory Asset Management LLC bought a new stake in Eli Lilly And Co during the second quarter worth $47,000. Personal Wealth Partners bought a new stake in Eli Lilly And Co during the second quarter worth $53,000. Finally, Kavar Capital Partners LLC bought a new stake in Eli Lilly And Co during the second quarter worth $55,000. Institutional investors own 76.78% of the company’s stock.

In related news, SVP Stephen F. Fry sold 9,452 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the transaction, the senior vice president now owns 100,211 shares in the company, valued at approximately $11,524,265. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now owns 38,306 shares in the company, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.

A number of analysts recently commented on the company. Bank of America set a $120.00 price target on Eli Lilly And Co and gave the stock a “neutral” rating in a report on Tuesday. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. Goldman Sachs Group assumed coverage on Eli Lilly And Co in a report on Tuesday, May 28th. They set a “buy” rating and a $135.00 price target on the stock. Finally, ValuEngine lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $122.93.

Shares of NYSE LLY traded down $0.46 during midday trading on Friday, reaching $111.01. The company had a trading volume of 126,750 shares, compared to its average volume of 3,204,832. Eli Lilly And Co has a one year low of $104.17 and a one year high of $132.13. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. The firm’s fifty day moving average price is $111.51 and its 200-day moving average price is $116.94. The stock has a market cap of $107.26 billion, a PE ratio of 19.98, a price-to-earnings-growth ratio of 1.96 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The company had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the company posted $1.48 EPS. Eli Lilly And Co’s revenue for the quarter was up .9% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly And Co will post 5.73 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were paid a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.32%. The ex-dividend date of this dividend was Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Understanding Options Trading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.